HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


L’Oréal first half sales

This article was originally published in The Rose Sheet

Executive Summary

Cosmetics revenue grew 4.1% like-for-like, or 3.5% on a reported basis, to $8.5 bil. (€1=$1.20) during the first half of 2005, French beauty company reports July 11. Sales of consumer products were up 4.1% like-for-like, or 3.7% on a reported basis, to $4.55 bil., led by the performance of L'Oréal Paris True Match and Maybelline New York Dream Matte Mousse foundations and L'Oréal Men Expert, firm says. Active cosmetics gained approximately 13% to $677.3 mil. on sales of Vichy and La-Roche Posay skin care brands. Luxury products grew 1.4% like-for-like to $1.97 bil., but were flat on a reported basis, boosted by sales of Armani Black Code fragrance for men and Armani Cosmetics, as well as Lancôme, Kiehl's and Biotherm products, according to L'Oréal. In North America, revenues were up 7.2% like-for-like, or 3.8% on a reported basis, to $2.17 bil., driven by consumer products including Garnier Fructis hair care...

You may also be interested in...


French company is evaluating Japanese cosmetics business Kanebo as a potential acquisition target, but declined to comment on specifics regarding its interest during Sept. 2 half year earnings presentation. "We are obliged to look at a dossier such as that one, as it is extremely rare...for a significant company in terms of market share in Japan to be up for sale," firm says. Japanese Industrial Revitalization Corporation currently is seeking a buyer for Kanebo. L'Oréal reported a 5.8% decline in net profit to $1.12 bil. (€1=$1.25), related to the deconsolidation of Sanofi-Synthelabo. Operating profit was flat at $1.39 bil. under new European accounting rules. L'Oréal reported first half sales in July (1"The Rose Sheet" July 18, 2005, In Brief)...

The Quality Lowdown: Import Alert Update

Crude heparin supplier Yibin Lihao headlines list of facilities in 12 countries added to the US FDA’s drug GMP import alert.

Novartis Pharma President Marie-France Tschudin On Inclisiran, Launches And More

Tschudin talked to Scrip about taking over as Novartis Pharmaceuticals president, why inclisiran is different from marketed PCSK9 inhibitors and prioritizing investment behind multiple new launches.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts